Deep Origin deploys AI-powered ADMET models across drug discovery programmes

Deep Origin and its partners have deployed AI-powered ADMET models in a pilot programme across four drug development organisations to improve early drug safety prediction. This effort is part of a $31.7 million ARPA-H funded initiative to create human-based in silico models to accelerate and enhance drug toxicity and safety assessments, with implications for FDA regulatory alignment and rare disease drug development.

This Wire brief sits within Fusion42's coverage of Drug Discovery.